179 filings
Page 3 of 9
S-8
ysgt7qr
8 Jun 22
Registration of securities for employees
4:01pm
8-K
lhe37xtuo 7vhrytjy90
8 Jun 22
Results of Operations and Financial Condition
7:05am
8-K
1pa3 mdzzl4
30 Mar 22
Regulation FD Disclosure
7:44am
8-K
06s gw2q58g
4 Feb 22
Company Ended the Quarter With Cash of Approximately $527.0 Million
7:09am
S-8
x7fv7jg59 il
10 Jan 22
Registration of securities for employees
4:31pm
8-K
zi9f4tcl
7 Jan 22
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
3:57pm
8-K
i6bv6yslh6yc0a2d4x
5 Jan 22
Regulation FD Disclosure
7:38am
8-K
p8kdyb
30 Dec 21
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
7:05am
8-K
q82 le5lswpxr0k49
23 Nov 21
Entry into a Material Definitive Agreement
4:27pm
8-K
63aaj
17 Nov 21
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
8:36am
8-K
n979dre7huowy
5 Nov 21
Company Ended the Quarter With Cash of Approximately $559 Million
7:39am
8-K
qga8ww
27 Sep 21
Immunovant to Participate in Roivant R&D Day 2021
8:23am
8-K
zss77fjiqb0w6lb4gg9
15 Sep 21
Immunovant Appoints Renee Barnett as Chief Financial Officer
7:23am
8-K
u1edybv
9 Aug 21
Company Ended the Quarter With Cash of Approximately $379 Million
6:56am
PRE 14A
8j5s 38zhaggwu0t
2 Aug 21
Preliminary proxy
4:31pm